STMN1 and melanoma: In a large‐scale phase 2–3 RCT (NCT03470922), nivolumab plus relatlimab showed remarkably extended PFS compared to nivolumab monotherapy among melanoma patients with LAG‐3 ≥ 1% (12.6 vs 4.8 months).[5] Consequently, simultaneously quantifying the expression levels of immunotherapy markers LAG‐3 and PD‐L1 is of great importance to select immunotherapy regimens.